U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07295028) titled 'Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults' on Nov. 24.
Brief Summary: This study is being done to find out how safe and effective a new combined vaccine candidate, called VXB-251, is for older adults. The vaccine candidate is designed to protect against three common viruses that can cause respiratory tract infections:
* RSV (respiratory syncytial virus)
* hMPV (human metapneumovirus)
* PIV3 (parainfluenza virus type 3)
Two components of this vaccine (RSV and hMPV) have already been tested in people before, as part of another study for a two-in-one vaccine. However, this is the first time that ...